Readoutin 45d
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — TQB2102 for Injection
Phase 3 primary completion: A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Breast Cancer